Skip to content

Clinical trials

Phase 1 Astrocytoma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Astrocytoma Phase: Phase 1 Country / region: United States Clear all

238 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20009
200111
200213
20036
20049
200516
200610
20075
20089
200912
201016
20117
201210
20138
20147
20155
201611
20176
20183
20197
20204
20212
20224
20235
20241
20258
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed161
Terminated37
Recruiting16
Active, not recruiting15
Unknown status4
Withdrawn4
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)42
Pediatric Brain Tumor Consortium14
City of Hope Medical Center12
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins12
Children's Oncology Group10
Duke University10
Memorial Sloan Kettering Cancer Center6
Jonsson Comprehensive Cancer Center5
Mayo Clinic5
National Institutes of Health Clinical Center (CC)5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Astrocytoma238
Glioblastoma169
Oligodendroglioma145
Glioma126
Brain Neoplasms117
Gliosarcoma93
Central Nervous System Neoplasms87
Medulloblastoma69
Ependymoma48
Choroid Plexus Neoplasms41

Trials

Showing 1 to 25 of 238. Each trial links to its page on Pharma Observatory.

138 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.